In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In DESTINY-Breast06, this approach significantly reduced the risk of disease progression by 38%, compared with chemotherapy, and patients with HER2-ultralow expression appeared to derive as much benefit as those in the HER2-low subset.
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024 Debates and Didactics in Hematology and Oncology conference by two myeloma experts from Emory University Winship Cancer Center,1 which sponsors the annual event. Ajay K. Nooka, MD, MPH, Professor and Director of the Myeloma Program, and Nisha S. Joseph, MD, Associate Professor, both of the Department of Hematology and Medical Oncology at Emory, reviewed the data from pivotal trials that may inform clinicians in their treatment selection.
With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission.
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of lymph node–only metastases (ie, cN+ urothelial cancer), providing optimism that patients with this type of urothelial carcinoma may achieve long-term remission. These findings were based on a post hoc subset analysis of the phase III CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard radiotherapy in patients with inoperable stage III non–small cell lung cancer (NSCLC).
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
In a meta-analysis reported in JAMA Oncology, Villacampa et al found that the addition of neoadjuvant immune checkpoint inhibitor (ICI) treatment to chemotherapy was associated with improved outcomes among subgroups of patients with early breast cancer. Study Details A literature search through...
It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...
Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...
As reported in The Lancet Oncology by Oliveira et al, patient-reported outcomes in the phase III CAPItello-291 trial indicate a delay in deterioration of health-related quality of life (HRQOL) with capivasertib/fulvestrant vs placebo/fulvestrant in patients with previously treated hormone...
In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell ...